Kimberly A. Skelding MD (She/Her)
Interventional Cardiology, Preventive Cardiology
Structural and Interventional Cardiologist, researcher, educator and administrator.
Join to View Full Profile
377 Jersey Avenue450Jersey City, NJ 07302
Phone+1 201-915-2525
Fax+1 201-915-2945
Dr. Skelding is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Kimberly Skelding is the Division Chief for Cardiovascular Services, Chief of Cardiology at RWJBarnabas Health in Jersey City, NJ. An interventional cardiologist who specializes in the treatment of valvular and coronary heart disease. Lectures nationally and internationally. Published over 100 articles in her field. A nationally known thought leader, researcher and clinician.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Interventional Cardiology, 2004 - 2005
Corewell Health William Beaumont University HospitalFellowship, Cardiovascular Disease, 1999 - 2002
Geisinger Health System (Danville)Residency, Internal Medicine, 1996 - 1999
Northwestern University The Feinberg School of MedicineClass of 1996
Certifications & Licensure
NJ State Medical License 2023 - 2027
VA State Medical License 2019 - 2024
WA State Medical License 2020 - 2024
PA State Medical License 1997 - 2022
GA State Medical License 2020 - 2021
AL State Medical License 2017 - 2020
MI State Medical License 1998 - 2005
American Board of Internal Medicine Cardiovascular Disease- American Board of Internal Medicine Interventional Cardiology
- Join now to see all
Awards, Honors, & Recognition
- Fellow SCAI
- Fellow American Heart Association
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
- Join now to see all
Clinical Trials
- Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk Subjects Who Need Aortic Valve Replacement Start of enrollment: 2010 Dec 10
- Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).
- Safety & Efficacy Study of the Medtronic CoreValve® System-Treatment of Symptomatic Severe Aortic Stenosis With Significant Comorbidities in Extreme Risk Subjects Who Need Aortic Valve Replacement
- Join now to see all
Publications & Presentations
PubMed
- Upper Extremity Venous Access.Kajol Shah, Ian C Gilchrist, Kimberly A Skelding
Interventional Cardiology Clinics. 2025-10-01 - 3 citationsImpact of Transcatheter or Surgical Aortic Valve Performance on 5-Year Outcomes in Patients at ≥ Intermediate Risk.Steven J Yakubov, Nicolas M Van Mieghem, Jae K Oh, Saki Ito, Kendra J Grubb
Journal of the American College of Cardiology. 2025-04-08 - 2 citationsOccupational Health Hazards in the Cardiac Catheterization Laboratory: Results of the 2023 SCAI Survey.Islam Abudayyeh, Allison G Dupont, James B Hermiller, Justine Mascarenhas, Poonam Velagapudi
Journal of the Society for Cardiovascular Angiography & Interventions. 2025-04-01
Press Mentions
Registry Data Rekindle Talk over the Best Valve for TAVI in Small AnnuliMay 19th, 2025- New SCAI President Lists Advocacy, Cardiogenic Shock Among His Top PrioritiesMay 5th, 2025
- SMART: Small Aortic Annuli Still Fare Best with Self-Expandable Valves at 2 YearsMarch 10th, 2025
- Join now to see all
Professional Memberships
- Fellow
- Fellow
- Society for Cardiovascular Angiography and InterventionFellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
